Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Aficamten [inn]
2. Aficamten [usan]
3. 2364554-48-1
4. B1i77mh6k1
5. Chembl4847050
6. Ck-3773274
7. 1h-pyrazole-4-carboxamide, N-((1r)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-
8. N-((1r)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)- 1-methyl-1h-pyrazole-4-carboxamide
9. Unii-b1i77mh6k1
10. Schembl21179170
11. Gtpl11524
12. Ex-a5344
13. Bdbm50575173
14. Ck-274
15. Who 11544
16. Ck3773274
17. Hy-139465
18. Ck-3773274;ck-274
19. Cs-0202223
20. (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
21. N-[(1r)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl]-1-methylpyrazole-4-carboxamide
| Molecular Weight | 337.4 g/mol |
|---|---|
| Molecular Formula | C18H19N5O2 |
| XLogP3 | 2.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 4 |
| Exact Mass | 337.15387487 g/mol |
| Monoisotopic Mass | 337.15387487 g/mol |
| Topological Polar Surface Area | 85.8 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 490 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
CK-3773274 (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor. It is under phase 3 clinical development fot the treatment of obstructive hypertrophic cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CK-3773274
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 23, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cytokinetics Announces EMA Validation Of Aficamten for Obstructive Cardiomyopathy
Details : CK-3773274 (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor. It is under phase 3 clinical development fot the treatment of obstructive hypertrophic cardiomyopathy.
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2024
Details:
Sanofi will acquire CORXEL’s rights relating to CK-3773274 (aficamten) in Greater China> It is being evaluated for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CK-3773274
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 20, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Cytokinetics Partners with Sanofi To Develop Aficamten in Greater China
Details : Sanofi will acquire CORXEL’s rights relating to CK-3773274 (aficamten) in Greater China> It is being evaluated for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy.
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 20, 2024
Details:
CK-3773274 (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor. It is under development for the treatment of obstructive hypertrophic cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CK-3773274
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 02, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cytokinetics Submits Aficamten NDA for Hypertrophic Cardiomyopathy Treatment
Details : CK-3773274 (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor. It is under development for the treatment of obstructive hypertrophic cardiomyopathy.
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2024
Details:
The agreement aims for the development and commercialization of aficamten, a next-in-class cardiac myosin inhibitor, in Japan for the treatment of patients with obstructive and non-obstructive HCM.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CK-3773274
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Bayer AG
Deal Size: $630.0 million Upfront Cash: $52.0 million
Deal Type: Collaboration November 19, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bayer AG
Deal Size : $630.0 million
Deal Type : Collaboration
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
Details : The agreement aims for the development and commercialization of aficamten, a next-in-class cardiac myosin inhibitor, in Japan for the treatment of patients with obstructive and non-obstructive HCM.
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : $52.0 million
November 19, 2024
Details:
CK-3773274 (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor. It is under clinical development for obstructive hypertrophic cardiomyopathy in pediatric population.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CK-3773274
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 05, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cytokinetics Starts CEDAR-HCM Trial for Pediatric Obstructive Hypertrophic Cardiomyopathy
Details : CK-3773274 (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor. It is under clinical development for obstructive hypertrophic cardiomyopathy in pediatric population.
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 05, 2024
Details:
CK-3773274 (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor. It is under clinical development for the treatment of obstructive hypertrophic cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CK-3773274
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 17, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cytokinetics Announces Initiation of Ph 1 Study of Aficamten in Japanese Participants
Details : CK-3773274 (aficamten) is an investigational selective, small molecule cardiac myosin inhibitor. It is under clinical development for the treatment of obstructive hypertrophic cardiomyopathy.
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2024
Details:
The company will use the proceeds for commercial launch readiness activities and for development program of CK-3773274 (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CK-3773274
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: J.P. Morgan
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 28, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $500.0 million
Deal Type : Public Offering
Cytokinetics Announces Closing of Public Offering of Common Stock
Details : The company will use the proceeds for commercial launch readiness activities and for development program of CK-3773274 (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy.
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 28, 2024
Details:
The company intends to use net proceeds for commercial launch readiness and continuing development of CK-3773274 (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CK-3773274
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: J.P. Morgan
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 22, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $500.0 million
Deal Type : Public Offering
Cytokinetics Announces Pricing of Public Offering of Common Stock
Details : The company intends to use net proceeds for commercial launch readiness and continuing development of CK-3773274 (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy.
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 22, 2024
Details:
The collaboration providing capital to support the commercialization of CK-3773274 (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CK-3773274
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Royalty Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 22, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Royalty Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Cytokinetics and Royalty Pharma Announce $575 Million Funding Collaboration
Details : The collaboration providing capital to support the commercialization of CK-3773274 (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 22, 2024
Details:
The financing will enable the company to support Ji Xing Pharmaceuticals in the commercialization of JIXING’s pipeline assets in the areas of cardiovascular diseases and ophthalmology.
Lead Product(s): Aficamten
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CK-3773274
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Bayer AG
Deal Size: $162.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing January 06, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bayer AG
Deal Size : $162.0 million
Deal Type : Series D Financing
Bayer and RTW Investments Lead Series D in Chinese Biotech Ji Xing Pharmaceuticals
Details : The financing will enable the company to support Ji Xing Pharmaceuticals in the commercialization of JIXING’s pipeline assets in the areas of cardiovascular diseases and ophthalmology.
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 06, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
ABOUT THIS PAGE
77
PharmaCompass offers a list of Aficamten API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Aficamten manufacturer or Aficamten supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Aficamten manufacturer or Aficamten supplier.
PharmaCompass also assists you with knowing the Aficamten API Price utilized in the formulation of products. Aficamten API Price is not always fixed or binding as the Aficamten Price is obtained through a variety of data sources. The Aficamten Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Aficamten manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aficamten, including repackagers and relabelers. The FDA regulates Aficamten manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aficamten API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Aficamten supplier is an individual or a company that provides Aficamten active pharmaceutical ingredient (API) or Aficamten finished formulations upon request. The Aficamten suppliers may include Aficamten API manufacturers, exporters, distributors and traders.
click here to find a list of Aficamten suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Aficamten as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Aficamten API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Aficamten as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Aficamten and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Aficamten NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Aficamten suppliers with NDC on PharmaCompass.
Aficamten Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aficamten GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aficamten GMP manufacturer or Aficamten GMP API supplier for your needs.
A Aficamten CoA (Certificate of Analysis) is a formal document that attests to Aficamten's compliance with Aficamten specifications and serves as a tool for batch-level quality control.
Aficamten CoA mostly includes findings from lab analyses of a specific batch. For each Aficamten CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aficamten may be tested according to a variety of international standards, such as European Pharmacopoeia (Aficamten EP), Aficamten JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aficamten USP).
